Weak Sales Prompt Pfizer to Cancel Diabetes Drug

New York Times: "Pfizer said yesterday that it would stop selling Exubera, its inhaled insulin, less than two years after introducing the drug. Despite Pfizer’s heavy promotion, Exubera’s sales were minuscule, with prescriptions amounting to less than 1 percent of the insulin market. Skip to next paragraph John Sommers II/Reuters A diabetes patient, Daniel Barrow, uses an Exubera inhaler. Some patients found the device cumbersome and inconvenient.

SmallShop Drug Search results

FDA Approves First Ever Inhaled Insulin Combination Product for ...
Exubera, an inhaled powder form of recombinant human insulin (rDNA) for the ... Exubera is a powdered form of insulin that is able to be inhaled into the ...www.fda.gov/bbs/topics/news/2006/NEW01304.html